首页 > 最新文献

Substance Abuse and Rehabilitation最新文献

英文 中文
A review of gambling disorder and substance use disorders. 综述赌博障碍和药物使用障碍。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2016-03-17 eCollection Date: 2016-01-01 DOI: 10.2147/SAR.S83460
Carla J Rash, Jeremiah Weinstock, Ryan Van Patten

In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), gambling disorder was recategorized from the "Impulse Control Disorder" section to the newly expanded "Substance-related and Addictive Disorders" section. With this move, gambling disorder has become the first recognized nonsubstance behavioral addiction, implying many shared features between gambling disorder and substance use disorders. This review examines these similarities, as well as differences, between gambling and substance-related disorders. Diagnostic criteria, comorbidity, genetic and physiological underpinnings, and treatment approaches are discussed.

在《精神疾病诊断与统计手册》(DSM-5)第五版中,赌博障碍从 "冲动控制障碍 "部分重新归类到新扩展的 "物质相关和成瘾障碍 "部分。此举使赌博障碍成为第一个被认可的非物质行为成瘾症,这意味着赌博障碍与物质使用障碍之间存在许多共同特征。本综述将探讨赌博障碍与药物相关障碍之间的相似之处和不同之处。文中讨论了诊断标准、合并症、遗传和生理基础以及治疗方法。
{"title":"A review of gambling disorder and substance use disorders.","authors":"Carla J Rash, Jeremiah Weinstock, Ryan Van Patten","doi":"10.2147/SAR.S83460","DOIUrl":"10.2147/SAR.S83460","url":null,"abstract":"<p><p>In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), gambling disorder was recategorized from the \"Impulse Control Disorder\" section to the newly expanded \"Substance-related and Addictive Disorders\" section. With this move, gambling disorder has become the first recognized nonsubstance behavioral addiction, implying many shared features between gambling disorder and substance use disorders. This review examines these similarities, as well as differences, between gambling and substance-related disorders. Diagnostic criteria, comorbidity, genetic and physiological underpinnings, and treatment approaches are discussed. </p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"7 1","pages":"3-13"},"PeriodicalIF":1.8,"publicationDate":"2016-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68481292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids CEDIA丁丙诺啡测定在滥用药物筛选中的交叉反应性:阿片类药物剂量和代谢物的影响
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-10-28 DOI: 10.2147/SAR.S88935
J. A. Berg, J. Schjøtt, K. O. Fossan, Bettina Riedel
Purpose The cloned enzyme donor immunoassay (CEDIA) for buprenorphine is applied for both urine drugs-of-abuse screening and compliance monitoring. Sensitivity, specificity, and optimal cutoff of this assay have differed between studies. This may indicate that cross-reactivity has to be taken into account during assay evaluation. We therefore investigated the performance of the CEDIA buprenorphine assay for use in our patient population and explored the impact of cross-reactivity on assay accuracy. Methods The CEDIA buprenorphine assay and high-performance liquid chromatography–tandem mass spectrometry were employed to analyze drugs-of-abuse in urine samples from a healthy drug-naïve male volunteer after intake of two tablets of a prescription drug containing 400 mg paracetamol +30 mg codeine phosphate, and in urine samples (n=2,272) from drug-addicted patients. Receiver operating characteristic analyses were performed to express the diagnostic accuracy of the CEDIA buprenorphine assay. Results CEDIA buprenorphine was positive in one urine sample from the drug-naïve person after intake of the prescription drug. Twenty-five (1.1%) of the patient urine samples were positive for buprenorphine by CEDIA, but negative by high-performance liquid chromatography–tandem mass spectrometry. Codeine, morphine, and their respective metabolites were prevalent in samples that were false positive for buprenorphine. The specificity of the CEDIA buprenorphine assay increased to 99.7% when the cutoff was increased from 5 ng/mL to 10 ng/mL. Conclusion Intake of a therapeutic dose of codeine can yield a false-positive CEDIA buprenorphine result. Additive effects from metabolites of codeine contribute to cross-reactivity in concentrations much lower than listed in the manufacturer’s cross-reactivity guide. Raising the cutoff from 5 ng/mL to 10 ng/mL increased the diagnostic accuracy. Clinicians should be informed about the risk of false-positive results with the CEDIA buprenorphine assay.
目的应用丁丙诺啡克隆酶供体免疫分析法(CEDIA)进行尿液滥用药物筛查和依从性监测。灵敏度、特异性和最佳截止在不同的研究中有所不同。这可能表明在分析评估时必须考虑交叉反应性。因此,我们研究了CEDIA丁丙诺啡测定在我们患者群体中的性能,并探讨了交叉反应性对测定准确性的影响。方法采用CEDIA丁丙诺啡测定法和高效液相色谱-串联质谱法分析健康男性志愿者drug-naïve在服用含400mg对乙酰氨基酚+ 30mg磷酸可待因的2片处方药后的尿液样本和吸毒成瘾患者尿液样本(n= 2272)中的滥用药物。进行受试者工作特征分析以表达CEDIA丁丙诺啡检测的诊断准确性。结果drug-naïve患者用药后1例尿液CEDIA检测丁丙诺啡阳性。25例(1.1%)患者尿液CEDIA检测丁丙诺啡阳性,高效液相色谱-串联质谱检测阴性。在丁丙诺啡假阳性的样本中,可待因、吗啡及其各自的代谢物普遍存在。当检测下限从5 ng/mL增加到10 ng/mL时,CEDIA丁丙诺啡检测的特异性提高到99.7%。结论服用治疗剂量的可待因可导致CEDIA丁丙诺啡假阳性。可待因代谢物的加性效应导致交叉反应,其浓度远低于制造商交叉反应指南中列出的浓度。将临界值从5 ng/mL提高到10 ng/mL,可提高诊断准确性。临床医生应了解CEDIA丁丙诺啡测定假阳性结果的风险。
{"title":"Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids","authors":"J. A. Berg, J. Schjøtt, K. O. Fossan, Bettina Riedel","doi":"10.2147/SAR.S88935","DOIUrl":"https://doi.org/10.2147/SAR.S88935","url":null,"abstract":"Purpose The cloned enzyme donor immunoassay (CEDIA) for buprenorphine is applied for both urine drugs-of-abuse screening and compliance monitoring. Sensitivity, specificity, and optimal cutoff of this assay have differed between studies. This may indicate that cross-reactivity has to be taken into account during assay evaluation. We therefore investigated the performance of the CEDIA buprenorphine assay for use in our patient population and explored the impact of cross-reactivity on assay accuracy. Methods The CEDIA buprenorphine assay and high-performance liquid chromatography–tandem mass spectrometry were employed to analyze drugs-of-abuse in urine samples from a healthy drug-naïve male volunteer after intake of two tablets of a prescription drug containing 400 mg paracetamol +30 mg codeine phosphate, and in urine samples (n=2,272) from drug-addicted patients. Receiver operating characteristic analyses were performed to express the diagnostic accuracy of the CEDIA buprenorphine assay. Results CEDIA buprenorphine was positive in one urine sample from the drug-naïve person after intake of the prescription drug. Twenty-five (1.1%) of the patient urine samples were positive for buprenorphine by CEDIA, but negative by high-performance liquid chromatography–tandem mass spectrometry. Codeine, morphine, and their respective metabolites were prevalent in samples that were false positive for buprenorphine. The specificity of the CEDIA buprenorphine assay increased to 99.7% when the cutoff was increased from 5 ng/mL to 10 ng/mL. Conclusion Intake of a therapeutic dose of codeine can yield a false-positive CEDIA buprenorphine result. Additive effects from metabolites of codeine contribute to cross-reactivity in concentrations much lower than listed in the manufacturer’s cross-reactivity guide. Raising the cutoff from 5 ng/mL to 10 ng/mL increased the diagnostic accuracy. Clinicians should be informed about the risk of false-positive results with the CEDIA buprenorphine assay.","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 1","pages":"131 - 139"},"PeriodicalIF":1.8,"publicationDate":"2015-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S88935","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68481310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Motivation to maintain sobriety among residents of sober living recovery homes. 清醒生活康复之家的居民保持清醒的动机。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-09-11 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S89361
Douglas L Polcin, Rachael Korcha

Background: The study of motivation in the substance abuse field has typically examined the extent to which substance users want to quit or reduce substance use. Less frequently examined is the desire to maintain sobriety after achieving abstinence. The current study examined motivation to maintain sobriety among residents of sober living houses (SLHs), a type of recovery home for individuals with alcohol and drug problems. Previous research on this population showed favorable longitudinal outcomes over 18 months. Resident views about the costs of not using substances (ie, the difficulties encountered when not using), as well as the perceived benefits of not using, were strong predictors of substance use outcomes.

Methods: This study adds to these findings by conducting two focus groups with individuals familiar with the structure and day-to-day operations of SLHs, including administrators of SLH organizations, owners, and peer managers.

Results: Focus group results supported the importance of costs and benefits as motivational forces influencing abstinence. However, participants also emphasized characteristics of the sober living recovery environment as important factors influencing motivation. Interactions among recovering peers offer unique opportunities for feeling understood, recognizing vulnerability in others, identifying with the recovery processes of others, receiving supportive confrontation, and engaging in mutual accountability. These experiences are important elements of motivation that become activated by involvement in the SLH environment and are difficult to replicate outside of that context.

Conclusion: In addition to recognizing how motivation can be enhanced by addressing costs and benefits experienced by individuals, operators of recovery homes need to understand motivation as a function of the recovery home social environment. Additional studies are needed on motivation as a longitudinal construct in a variety of peer-oriented environments. Studies are also needed to better specify interactions within SLHs that increase and hinder motivation among different types of residents.

背景:药物滥用领域的动机研究通常考察药物使用者想要戒烟或减少药物使用的程度。较少被检查的是在戒酒后保持清醒的愿望。目前的研究调查了清醒生活之家(SLHs)的居民保持清醒的动机,SLHs是一种为有酒精和毒品问题的个人提供的康复之家。先前对这一人群的研究显示,18个月后的纵向结果良好。居民对不使用药物的成本(即不使用时遇到的困难)的看法以及不使用药物的感知好处是药物使用结果的有力预测因素。方法:本研究通过与熟悉SLH组织结构和日常运作的个人进行两个焦点小组,包括SLH组织的管理者、所有者和同伴经理,来补充这些发现。结果:焦点小组结果支持成本和收益作为影响禁欲的动机力量的重要性。然而,参与者也强调清醒生活恢复环境的特征是影响动机的重要因素。康复中的同伴之间的互动提供了独特的机会,让他们感到被理解,认识到他人的脆弱,认同他人的康复过程,接受支持性的对抗,并参与相互的责任。这些经历是动机的重要组成部分,通过参与SLH环境而被激活,并且很难在该环境之外复制。结论:除了认识到如何通过解决个人经历的成本和收益来提高动机外,康复之家的经营者还需要了解动机是康复之家社会环境的一个功能。需要进一步研究动机作为纵向结构在各种同伴导向的环境。还需要进行研究,以更好地确定slh内的相互作用,这些相互作用会增加或阻碍不同类型居民的动机。
{"title":"Motivation to maintain sobriety among residents of sober living recovery homes.","authors":"Douglas L Polcin,&nbsp;Rachael Korcha","doi":"10.2147/SAR.S89361","DOIUrl":"https://doi.org/10.2147/SAR.S89361","url":null,"abstract":"<p><strong>Background: </strong>The study of motivation in the substance abuse field has typically examined the extent to which substance users want to quit or reduce substance use. Less frequently examined is the desire to maintain sobriety after achieving abstinence. The current study examined motivation to maintain sobriety among residents of sober living houses (SLHs), a type of recovery home for individuals with alcohol and drug problems. Previous research on this population showed favorable longitudinal outcomes over 18 months. Resident views about the costs of not using substances (ie, the difficulties encountered when not using), as well as the perceived benefits of not using, were strong predictors of substance use outcomes.</p><p><strong>Methods: </strong>This study adds to these findings by conducting two focus groups with individuals familiar with the structure and day-to-day operations of SLHs, including administrators of SLH organizations, owners, and peer managers.</p><p><strong>Results: </strong>Focus group results supported the importance of costs and benefits as motivational forces influencing abstinence. However, participants also emphasized characteristics of the sober living recovery environment as important factors influencing motivation. Interactions among recovering peers offer unique opportunities for feeling understood, recognizing vulnerability in others, identifying with the recovery processes of others, receiving supportive confrontation, and engaging in mutual accountability. These experiences are important elements of motivation that become activated by involvement in the SLH environment and are difficult to replicate outside of that context.</p><p><strong>Conclusion: </strong>In addition to recognizing how motivation can be enhanced by addressing costs and benefits experienced by individuals, operators of recovery homes need to understand motivation as a function of the recovery home social environment. Additional studies are needed on motivation as a longitudinal construct in a variety of peer-oriented environments. Studies are also needed to better specify interactions within SLHs that increase and hinder motivation among different types of residents.</p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"103-11"},"PeriodicalIF":1.8,"publicationDate":"2015-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S89361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34021947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
The pharmacology of neurokinin receptors in addiction: prospects for therapy. 成瘾中神经激肽受体的药理学:治疗前景。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-09-07 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S70350
Alexander J Sandweiss, Todd W Vanderah

Addiction is a chronic disorder in which consumption of a substance or a habitual behavior becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) is an undecapeptide and was the first neuropeptide of the neurokinin family to be discovered. The subsequent decades of research after its discovery implicated SP and its neurokinin relatives as neurotransmitters involved in the modulation of the reward pathway. Here, we review the neurokinin literature, giving a brief historical perspective of neurokinin pharmacology, localization in various brain regions involved in addictive behaviors, and the functional aspects of neurokinin pharmacology in relation to reward in preclinical models of addiction that have shaped the rational drug design of neurokinin antagonists that could translate into human research. Finally, we will cover the clinical investigations using neurokinin antagonists and discuss their potential as a therapy for drug abuse.

成瘾是一种慢性疾病,对某种物质的消费或习惯性行为变得强迫性,并且经常反复发作,尽管有不良后果。p物质(SP)是一种非肽,是神经激肽家族中第一个被发现的神经肽。在其发现之后的几十年的研究表明SP及其神经激肽亲戚是参与调节奖赏通路的神经递质。在这里,我们回顾了神经激肽的文献,给出了神经激肽药理学的简要历史观点,在涉及成瘾行为的不同大脑区域的定位,以及神经激肽药理学在成瘾的临床前模型中与奖励相关的功能方面,这些方面已经形成了神经激肽拮抗剂的合理药物设计,可以转化为人类研究。最后,我们将介绍使用神经激肽拮抗剂的临床研究,并讨论它们作为药物滥用治疗的潜力。
{"title":"The pharmacology of neurokinin receptors in addiction: prospects for therapy.","authors":"Alexander J Sandweiss,&nbsp;Todd W Vanderah","doi":"10.2147/SAR.S70350","DOIUrl":"https://doi.org/10.2147/SAR.S70350","url":null,"abstract":"<p><p>Addiction is a chronic disorder in which consumption of a substance or a habitual behavior becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) is an undecapeptide and was the first neuropeptide of the neurokinin family to be discovered. The subsequent decades of research after its discovery implicated SP and its neurokinin relatives as neurotransmitters involved in the modulation of the reward pathway. Here, we review the neurokinin literature, giving a brief historical perspective of neurokinin pharmacology, localization in various brain regions involved in addictive behaviors, and the functional aspects of neurokinin pharmacology in relation to reward in preclinical models of addiction that have shaped the rational drug design of neurokinin antagonists that could translate into human research. Finally, we will cover the clinical investigations using neurokinin antagonists and discuss their potential as a therapy for drug abuse. </p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"93-102"},"PeriodicalIF":1.8,"publicationDate":"2015-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S70350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34079783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 30
Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. 长期阿片类药物治疗患者的阿片类药物使用障碍:DSM-5最终诊断标准对患病率和相关因素的影响
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-08-19 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S85667
Joseph A Boscarino, Stuart N Hoffman, John J Han

Aims: Previously, we estimated the prevalence and risk factors for prescription opioid-use disorder among outpatients on opioid therapy using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 and DSM-4 criteria. However, at the time, the DSM-5 criteria were not finalized. In the current study, we analyzed these data using the final DSM-5 criteria and compared these results.

Methods: Using electronic records from a large US health care system, we identified outpatients receiving five or more prescription orders for opioid therapy in the past 12 months for noncancer pain (mean prescription orders =10.72; standard deviation =4.96). In 2008, we completed diagnostic interviews with 705 of these patients using the DSM-4 criteria. In the current study, we reassessed these results using the final DSM-5 criteria.

Results: The lifetime prevalence of DSM-5 opioid-use disorders using the final DSM-5 criteria was 58.7% for no or few symptoms (<2), 28.1% for mild symptoms (2-3), 9.7% for moderate symptoms (4-5), and 3.5% for severe symptoms (six or more). Thus, the lifetime prevalence of "any" prescription opioid-use disorder in this cohort was 41.3% (95% confidence interval [CI] =37.6-45.0). A comparison to the DSM-4 criteria indicated that the majority of patients with lifetime DSM-4 opioid dependence were now classified as having mild opioid-use disorder, based on the DSM-5 criteria (53.6%; 95% CI =44.1-62.8). In ordinal logistic regression predicting no/few, mild, moderate, and severe opioid-use disorder, the best predictors were age <65 years, current pain impairment, trouble sleeping, suicidal thoughts, anxiety disorders, illicit drug use, and history of substance abuse treatment.

Conclusion: Given the final DSM-5 criteria, including the elimination of tolerance and withdrawal, inclusion of craving and abuse symptoms, and introduction of a new graded severity classification, the prevalence of opioid-use disorders has changed, while many of the DSM-4 risk factors for opioid dependence were similar. To our knowledge, this is one of the first studies to compare the final results for DSM-5 versus DSM-4 prescription opioid-use disorders among a high-risk patient population.

目的:先前,我们使用精神疾病诊断与统计手册(DSM)-5和DSM-4标准估计阿片类药物治疗门诊患者处方阿片类药物使用障碍的患病率和危险因素。然而,在当时,DSM-5标准还没有最终确定。在目前的研究中,我们使用最终的DSM-5标准分析这些数据并比较这些结果。方法:使用来自美国大型医疗保健系统的电子记录,我们确定了过去12个月内接受5个或更多阿片类药物治疗处方的门诊患者,用于治疗非癌性疼痛(平均处方订单=10.72;标准差=4.96)。2008年,我们使用DSM-4标准完成了对705名患者的诊断访谈。在目前的研究中,我们使用最终的DSM-5标准重新评估了这些结果。结果:使用最终DSM-5标准的DSM-5阿片类药物使用障碍的终生患病率为58.7%,无症状或很少症状(结论:鉴于最终DSM-5标准,包括消除耐受性和戒断,包括渴望和滥用症状,以及引入新的分级严重程度分类,阿片类药物使用障碍的患病率发生了变化,而许多DSM-4阿片类药物依赖的危险因素是相似的。据我们所知,这是在高危患者人群中比较DSM-5和DSM-4处方阿片类药物使用障碍最终结果的首批研究之一。
{"title":"Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates.","authors":"Joseph A Boscarino,&nbsp;Stuart N Hoffman,&nbsp;John J Han","doi":"10.2147/SAR.S85667","DOIUrl":"https://doi.org/10.2147/SAR.S85667","url":null,"abstract":"<p><strong>Aims: </strong>Previously, we estimated the prevalence and risk factors for prescription opioid-use disorder among outpatients on opioid therapy using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 and DSM-4 criteria. However, at the time, the DSM-5 criteria were not finalized. In the current study, we analyzed these data using the final DSM-5 criteria and compared these results.</p><p><strong>Methods: </strong>Using electronic records from a large US health care system, we identified outpatients receiving five or more prescription orders for opioid therapy in the past 12 months for noncancer pain (mean prescription orders =10.72; standard deviation =4.96). In 2008, we completed diagnostic interviews with 705 of these patients using the DSM-4 criteria. In the current study, we reassessed these results using the final DSM-5 criteria.</p><p><strong>Results: </strong>The lifetime prevalence of DSM-5 opioid-use disorders using the final DSM-5 criteria was 58.7% for no or few symptoms (<2), 28.1% for mild symptoms (2-3), 9.7% for moderate symptoms (4-5), and 3.5% for severe symptoms (six or more). Thus, the lifetime prevalence of \"any\" prescription opioid-use disorder in this cohort was 41.3% (95% confidence interval [CI] =37.6-45.0). A comparison to the DSM-4 criteria indicated that the majority of patients with lifetime DSM-4 opioid dependence were now classified as having mild opioid-use disorder, based on the DSM-5 criteria (53.6%; 95% CI =44.1-62.8). In ordinal logistic regression predicting no/few, mild, moderate, and severe opioid-use disorder, the best predictors were age <65 years, current pain impairment, trouble sleeping, suicidal thoughts, anxiety disorders, illicit drug use, and history of substance abuse treatment.</p><p><strong>Conclusion: </strong>Given the final DSM-5 criteria, including the elimination of tolerance and withdrawal, inclusion of craving and abuse symptoms, and introduction of a new graded severity classification, the prevalence of opioid-use disorders has changed, while many of the DSM-4 risk factors for opioid dependence were similar. To our knowledge, this is one of the first studies to compare the final results for DSM-5 versus DSM-4 prescription opioid-use disorders among a high-risk patient population.</p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"83-91"},"PeriodicalIF":1.8,"publicationDate":"2015-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S85667","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34129104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 76
Erratum: Nalmefene: a new approach to the treatment of alcohol dependence [Corrigendum]. 纳美芬:一种治疗酒精依赖的新方法[勘误]。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-07-07 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S88450
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Substance Abuse and Rehabilitation Publish your work in this journal
{"title":"Erratum: Nalmefene: a new approach to the treatment of alcohol dependence [Corrigendum].","authors":"","doi":"10.2147/SAR.S88450","DOIUrl":"https://doi.org/10.2147/SAR.S88450","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Substance Abuse and Rehabilitation Publish your work in this journal","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"81"},"PeriodicalIF":1.8,"publicationDate":"2015-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S88450","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34017782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing? 纳美芬和酒精依赖:新方法还是旧的不可接受的营销?
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-06-29 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S86007
Alain Braillon, Bernard Granger
{"title":"Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?","authors":"Alain Braillon,&nbsp;Bernard Granger","doi":"10.2147/SAR.S86007","DOIUrl":"https://doi.org/10.2147/SAR.S86007","url":null,"abstract":"","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"75-80"},"PeriodicalIF":1.8,"publicationDate":"2015-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S86007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34286280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. 哌甲酯治疗可卡因成瘾的临床潜力:对现有证据的回顾。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-06-17 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S50807
Kenneth M Dürsteler, Eva-Maria Berger, Johannes Strasser, Carlo Caflisch, Jochen Mutschler, Marcus Herdener, Marc Vogel

Background: Cocaine use continues to be a public health problem, yet there is no proven effective pharmacotherapy for cocaine dependence. A promising approach to treating cocaine dependence may be agonist-replacement therapy, which is already used effectively in the treatment of opioid and tobacco dependence. The replacement approach for cocaine dependence posits that administration of a long-acting stimulant medication should normalize the neurochemical and behavioral perturbations resulting from chronic cocaine use. One potential medication to be substituted for cocaine is methylphenidate (MPH), as this stimulant possesses pharmacobehavioral properties similar to those of cocaine.

Aim: To provide a qualitative review addressing the rationale for the use of MPH as a cocaine substitute and its clinical potential in the treatment of cocaine dependence.

Methods: We searched MEDLINE for clinical studies using MPH in patients with cocaine abuse/dependence and screened the bibliographies of the articles found for pertinent literature.

Results: MPH, like cocaine, increases synaptic dopamine by inhibiting dopamine reuptake. The discriminative properties, reinforcing potential, and subjective effects of MPH and cocaine are almost identical and, importantly, MPH has been found to substitute for cocaine in animals and human volunteers under laboratory conditions. When taken orally in therapeutic doses, its abuse liability, however, appears low, which is especially true for extended-release MPH preparations. Though there are promising data in the literature, mainly from case reports and open-label studies, the results of randomized controlled trials have been disappointing so far and do not corroborate the use of MPH as a substitute for cocaine dependence in patients without attention deficit hyperactivity disorder.

Conclusion: Clinical studies evaluating MPH substitution for cocaine dependence have provided inconsistent findings. However, the negative findings may be explained by specific study characteristics, among them dosing, duration of treatment, or sample size. This needs to be considered when discussing the potential of MPH as replacement therapy for cocaine dependence. Finally, based on the results, we suggest possible directions for future research.

背景:可卡因使用仍然是一个公共卫生问题,但目前尚无经证实有效的药物治疗可卡因依赖。治疗可卡因依赖的一种有希望的方法可能是激动剂替代疗法,这种疗法已经有效地用于治疗阿片类药物和烟草依赖。可卡因依赖的替代方法假定,服用长效兴奋剂药物应使长期使用可卡因引起的神经化学和行为紊乱正常化。一种可能取代可卡因的药物是哌醋甲酯(MPH),因为这种兴奋剂具有与可卡因相似的药物行为特性。目的:提供一个定性的回顾,解决使用MPH作为可卡因替代品的基本原理及其在治疗可卡因依赖的临床潜力。方法:我们在MEDLINE检索使用MPH治疗可卡因滥用/依赖患者的临床研究,并筛选相关文献的文献书目。结果:MPH与可卡因一样,通过抑制多巴胺再摄取而增加突触多巴胺。MPH和可卡因的鉴别特性、强化电位和主观效应几乎相同,重要的是,在实验室条件下,在动物和人类志愿者中发现MPH可以替代可卡因。然而,当以治疗剂量口服时,其滥用风险似乎很低,对于缓释MPH制剂尤其如此。虽然文献中有一些令人鼓舞的数据,主要来自病例报告和开放标签研究,但迄今为止随机对照试验的结果令人失望,并且不能证实在没有注意缺陷多动障碍的患者中使用MPH作为可卡因依赖的替代品。结论:评价MPH替代可卡因依赖的临床研究提供了不一致的结果。然而,阴性结果可以用特定的研究特征来解释,其中包括剂量、治疗持续时间或样本量。在讨论MPH作为可卡因依赖替代疗法的潜力时,需要考虑到这一点。最后,在此基础上提出了今后可能的研究方向。
{"title":"Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.","authors":"Kenneth M Dürsteler,&nbsp;Eva-Maria Berger,&nbsp;Johannes Strasser,&nbsp;Carlo Caflisch,&nbsp;Jochen Mutschler,&nbsp;Marcus Herdener,&nbsp;Marc Vogel","doi":"10.2147/SAR.S50807","DOIUrl":"https://doi.org/10.2147/SAR.S50807","url":null,"abstract":"<p><strong>Background: </strong>Cocaine use continues to be a public health problem, yet there is no proven effective pharmacotherapy for cocaine dependence. A promising approach to treating cocaine dependence may be agonist-replacement therapy, which is already used effectively in the treatment of opioid and tobacco dependence. The replacement approach for cocaine dependence posits that administration of a long-acting stimulant medication should normalize the neurochemical and behavioral perturbations resulting from chronic cocaine use. One potential medication to be substituted for cocaine is methylphenidate (MPH), as this stimulant possesses pharmacobehavioral properties similar to those of cocaine.</p><p><strong>Aim: </strong>To provide a qualitative review addressing the rationale for the use of MPH as a cocaine substitute and its clinical potential in the treatment of cocaine dependence.</p><p><strong>Methods: </strong>We searched MEDLINE for clinical studies using MPH in patients with cocaine abuse/dependence and screened the bibliographies of the articles found for pertinent literature.</p><p><strong>Results: </strong>MPH, like cocaine, increases synaptic dopamine by inhibiting dopamine reuptake. The discriminative properties, reinforcing potential, and subjective effects of MPH and cocaine are almost identical and, importantly, MPH has been found to substitute for cocaine in animals and human volunteers under laboratory conditions. When taken orally in therapeutic doses, its abuse liability, however, appears low, which is especially true for extended-release MPH preparations. Though there are promising data in the literature, mainly from case reports and open-label studies, the results of randomized controlled trials have been disappointing so far and do not corroborate the use of MPH as a substitute for cocaine dependence in patients without attention deficit hyperactivity disorder.</p><p><strong>Conclusion: </strong>Clinical studies evaluating MPH substitution for cocaine dependence have provided inconsistent findings. However, the negative findings may be explained by specific study characteristics, among them dosing, duration of treatment, or sample size. This needs to be considered when discussing the potential of MPH as replacement therapy for cocaine dependence. Finally, based on the results, we suggest possible directions for future research.</p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"61-74"},"PeriodicalIF":1.8,"publicationDate":"2015-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S50807","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33431980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a review. 50岁及以上美国人的性风险行为和艾滋病毒风险:综述。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-04-21 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S78808
Daniel J Pilowsky, Li-Tzy Wu

Although HIV-related sexual risk behaviors have been studied extensively in adolescents and young adults, there is limited information about these behaviors among older Americans, which make up a growing segment of the US population and an understudied population. This review of the literature dealing with sexual behaviors that increase the risk of becoming HIV-infected found a low prevalence of condom use among older adults, even when not in a long-term relationship with a single partner. A seminal study by Schick et al published in 2010 reported that the prevalence of condom use at last intercourse was highest among those aged 50-59 years (24.3%; 95% confidence interval, 15.6-35.8) and declined with age, with a 17.1% prevalence among those aged 60-69 years (17.1%; 95% confidence interval, 7.3-34.2). Studies have shown that older Americans may underestimate their risk of becoming HIV-infected. Substance use also increases the risk for sexual risk behaviors, and studies have indicated that the prevalence of substance use among older adults has increased in the past decade. As is the case with younger adults, the prevalence of HIV infections is elevated among ethnic minorities, drug users (eg, injection drug users), and men who have sex with men. When infected, older adults are likely to be diagnosed with HIV-related medical disorders later in the course of illness compared with their younger counterparts. Physicians are less likely to discuss sexual risk behaviors with older adults and to test them for HIV compared with younger adults. Thus, it is important to educate clinicians about sexual risk behaviors in the older age group and to design preventive interventions specifically designed for older adults.

尽管hiv相关的性风险行为已经在青少年和年轻人中得到了广泛的研究,但关于这些行为在美国老年人中的信息有限,而老年人在美国人口中所占的比例越来越大,而且研究不足。这篇关于增加艾滋病毒感染风险的性行为的文献综述发现,老年人使用避孕套的比例很低,即使他们没有长期的单一伴侣关系。Schick等人在2010年发表的一项开创性研究报告称,在50-59岁的人群中,最后一次性交使用避孕套的比例最高(24.3%;95%可信区间为15.6-35.8),并随着年龄的增长而下降,60-69岁人群患病率为17.1% (17.1%;95%置信区间,7.3-34.2)。研究表明,美国老年人可能低估了他们感染艾滋病毒的风险。药物使用也增加了性危险行为的风险,研究表明,在过去十年中,老年人中药物使用的流行率有所增加。与年轻人的情况一样,少数民族、吸毒者(如注射吸毒者)和男男性行为者中艾滋病毒感染的流行率上升。与年轻人相比,老年人一旦感染艾滋病毒,很可能在患病后期被诊断出患有与艾滋病毒相关的医学疾病。与年轻人相比,医生不太可能与老年人讨论性风险行为,也不太可能为他们检测艾滋病毒。因此,重要的是教育临床医生关于老年群体的性危险行为,并设计专门为老年人设计的预防干预措施。
{"title":"Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a review.","authors":"Daniel J Pilowsky,&nbsp;Li-Tzy Wu","doi":"10.2147/SAR.S78808","DOIUrl":"https://doi.org/10.2147/SAR.S78808","url":null,"abstract":"<p><p>Although HIV-related sexual risk behaviors have been studied extensively in adolescents and young adults, there is limited information about these behaviors among older Americans, which make up a growing segment of the US population and an understudied population. This review of the literature dealing with sexual behaviors that increase the risk of becoming HIV-infected found a low prevalence of condom use among older adults, even when not in a long-term relationship with a single partner. A seminal study by Schick et al published in 2010 reported that the prevalence of condom use at last intercourse was highest among those aged 50-59 years (24.3%; 95% confidence interval, 15.6-35.8) and declined with age, with a 17.1% prevalence among those aged 60-69 years (17.1%; 95% confidence interval, 7.3-34.2). Studies have shown that older Americans may underestimate their risk of becoming HIV-infected. Substance use also increases the risk for sexual risk behaviors, and studies have indicated that the prevalence of substance use among older adults has increased in the past decade. As is the case with younger adults, the prevalence of HIV infections is elevated among ethnic minorities, drug users (eg, injection drug users), and men who have sex with men. When infected, older adults are likely to be diagnosed with HIV-related medical disorders later in the course of illness compared with their younger counterparts. Physicians are less likely to discuss sexual risk behaviors with older adults and to test them for HIV compared with younger adults. Thus, it is important to educate clinicians about sexual risk behaviors in the older age group and to design preventive interventions specifically designed for older adults. </p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"51-60"},"PeriodicalIF":1.8,"publicationDate":"2015-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S78808","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33293643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence of and factors associated with regular khat chewing among university students in Ethiopia. 埃塞俄比亚大学生经常咀嚼阿拉伯茶的流行程度及其相关因素。
IF 1.8 Q1 SUBSTANCE ABUSE Pub Date : 2015-02-26 eCollection Date: 2015-01-01 DOI: 10.2147/SAR.S78773
Ayalew Astatkie, Meaza Demissie, Yemane Berhane, Alemayehu Worku

Purpose: Khat (Catha edulis) is commonly chewed for its psychostimulant and euphorigenic effects in Africa and the Arabian Peninsula. Students use it to help them study for long hours especially during the period of examination. However, how regularly khat is chewed among university students and its associated factors are not well documented. In this article we report on the prevalence of and factors associated with regular khat chewing among university students in Ethiopia.

Methods: We did a cross-sectional study from May 20, 2014 to June 23, 2014 on a sample of 1,255 regular students recruited from all campuses of Hawassa University, southern Ethiopia. The data were collected using self-administered questionnaires. We analyzed the data to identify factors associated with current regular khat chewing using complex sample adjusted logistic regression analysis.

Results: The prevalence of current regular khat chewing was 10.5% (95% confidence interval [CI]: 6.1%-14.9%). After controlling for sex, religion, year of study, having a father who chews khat, cigarette smoking and alcohol drinking in the adjusted logistic regression model, living off-campus in rented houses as compared to living in the university dormitory (adjusted odds ratio [95% CI] =8.09 [1.56-42.01]), and having friends who chew khat (adjusted odds ratio [95% CI] =4.62 [1.98-10.74]) were found to significantly increase the odds of current regular khat use.

Conclusion: Students living outside the university campus in rented houses compared to those living in dormitory and those with khat chewing peers are more likely to use khat. A multipronged prevention approach involving students, the university officials, the surrounding community, and regulatory bodies is required.

用途:阿拉伯茶(Catha edulis)在非洲和阿拉伯半岛常被咀嚼,因为它具有精神兴奋剂和欣快作用。学生们用它来帮助他们长时间学习,特别是在考试期间。然而,大学生咀嚼阿拉伯茶的频率及其相关因素并没有很好的记录。在这篇文章中,我们报告了埃塞俄比亚大学生中经常咀嚼阿拉伯茶的患病率和相关因素。方法:2014年5月20日至2014年6月23日,我们对来自埃塞俄比亚南部哈瓦萨大学各校区的1255名普通学生进行了横断面研究。数据是通过自我管理的问卷收集的。我们对数据进行分析,以确定与当前常规阿拉伯茶咀嚼相关的因素,使用复杂样本调整逻辑回归分析。结果:目前正常咀嚼阿拉伯茶的患病率为10.5%(95%可信区间[CI]: 6.1%-14.9%)。在调整后的logistic回归模型中控制了性别、宗教、学习年份、有嚼阿拉伯茶的父亲、吸烟和饮酒等因素后,发现与住在大学宿舍相比,住在校外租的房子里(调整后的优势比[95% CI] =8.09[1.56-42.01])和有嚼阿拉伯茶的朋友(调整后的优势比[95% CI] =4.62[1.98-10.74])显著增加了目前经常使用阿拉伯茶的几率。结论:住在校外出租屋的大学生比住在宿舍的大学生和有嚼阿拉伯茶同伴的大学生更倾向于使用阿拉伯茶。需要采取包括学生、大学官员、周边社区和监管机构在内的多管齐下的预防措施。
{"title":"Prevalence of and factors associated with regular khat chewing among university students in Ethiopia.","authors":"Ayalew Astatkie,&nbsp;Meaza Demissie,&nbsp;Yemane Berhane,&nbsp;Alemayehu Worku","doi":"10.2147/SAR.S78773","DOIUrl":"https://doi.org/10.2147/SAR.S78773","url":null,"abstract":"<p><strong>Purpose: </strong>Khat (Catha edulis) is commonly chewed for its psychostimulant and euphorigenic effects in Africa and the Arabian Peninsula. Students use it to help them study for long hours especially during the period of examination. However, how regularly khat is chewed among university students and its associated factors are not well documented. In this article we report on the prevalence of and factors associated with regular khat chewing among university students in Ethiopia.</p><p><strong>Methods: </strong>We did a cross-sectional study from May 20, 2014 to June 23, 2014 on a sample of 1,255 regular students recruited from all campuses of Hawassa University, southern Ethiopia. The data were collected using self-administered questionnaires. We analyzed the data to identify factors associated with current regular khat chewing using complex sample adjusted logistic regression analysis.</p><p><strong>Results: </strong>The prevalence of current regular khat chewing was 10.5% (95% confidence interval [CI]: 6.1%-14.9%). After controlling for sex, religion, year of study, having a father who chews khat, cigarette smoking and alcohol drinking in the adjusted logistic regression model, living off-campus in rented houses as compared to living in the university dormitory (adjusted odds ratio [95% CI] =8.09 [1.56-42.01]), and having friends who chew khat (adjusted odds ratio [95% CI] =4.62 [1.98-10.74]) were found to significantly increase the odds of current regular khat use.</p><p><strong>Conclusion: </strong>Students living outside the university campus in rented houses compared to those living in dormitory and those with khat chewing peers are more likely to use khat. A multipronged prevention approach involving students, the university officials, the surrounding community, and regulatory bodies is required.</p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"41-50"},"PeriodicalIF":1.8,"publicationDate":"2015-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S78773","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33113115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Substance Abuse and Rehabilitation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1